This brand name is authorized in United States
The drug ADDYI contains one active pharmaceutical ingredient (API):
1
Flibanserin
UNII 37JK4STR6Z - FLIBANSERIN
|
Flibanserin is a multifunctional serotonin agonist and antagonist used for the treatment of premenopausal women with hypoactive sexual desire disorder. In vitro, flibanserin acts as an agonist on 5-HT1A receptors and an antagonist on 5-HT2A receptors. It also has moderate antagonist activities at the 5-HT2B, 5-HT2C, and dopamine D4 receptors. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
ADDYI Film coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
G02CX02 | G Genito urinary system and sex hormones → G02 Other gynecologicals → G02C Other gynecologicals → G02CX Other gynecologicals | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: CA | Health Products and Food Branch | Identifier(s): 02473550 |
Country: US | FDA, National Drug Code | Identifier(s): 58604-214 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.